Signpath Pharma
May 14, 2021
Signpath Pharma (Signpath) has developed a platform technology (the CorreQT platform) which mitigates the cardiac side effects of other drugs, including cardiac arrhythmia and cardiac damage associated with chemotherapy. The company has partnerships and working relationships with laboratories, hospitals, and other companies in Canada, Europe, the U.S., and Asia. Using the CorreQT technology, Signpath is developing heart-safe versions of FDA approved drugs which cause dangerous arrhythmia side effects. Clinical testing for these targets is expected to begin in 2020.
Recent News
- Kelvyn Cullimore: An Unfair Penalty on Life-Saving Pills
- Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-Impermeable Endoprosthesis
- Merit Medical Releases 12-Month Efficacy Results for the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY® Arteriovenous Efficacy (WAVE) Trial
- Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology
- Kelvyn Cullimore Joins KSL Radio’s Inside Sources
- Ultradent Donating to Southern California Fire Relief